Clinical Efficacy Analysis of Entecavir in the Treatment of Decompensated Liver Cirrhosis after Viral Hepatitis B
Objective To analyze the clinical effect of entecavir in patients with decompensated liver cirrhosis after hepatitis viral hepatitis B.Methods From February 2021 to February 2024,98 patients with decompensated liver cir-rhosis after viral hepatitis B in Fujian Jian'ou Hospital were conveniently selected as the research objects.According to different treatment regimens,they were divided into two groups,49 cases in each group.The control group was treated with lamivudine tablets,and the observation group was treated with lanivudine tablets and entecavir tablets.Af-ter 6 months of treatment,the clinical efficacy,liver function indexes and liver fibrosis indexes of the two groups were compared,and the adverse reactions occurred during the medication were counted.Results The total effective rate of treatment in the observation group was 93.88%(46/49),which was higher than that of the control group 79.59%(39/49),and the difference was statistically significant(χ2=4.346,P<0.05).After 6 months of treatment,the albumin level of the observation group was higher than that of the control group,and the levels of aspartate transaminase,alanine transaminase and total bilirubin were lower than those of the control group,the differences were statistically significant(all P<0.05).After 6 months of treatment,the levels of liver fibrosis indexes in the observation group were lower than those in the total control group,and the differences were statistically significant(P<0.05).There was no significant dif-ference in the total incidence of adverse drug reactions between the two groups(P>0.05).Conclusion Entecavir has a great clinical effect in the treatment of decompensated liver cirrhosis after viral hepatitis B,which can effectively im-prove the liver function and liver fibrosis indexes of patients,and the combination of drugs adverse reactions were less.
NETL
NSTL
万方数据
